<DOC>
	<DOCNO>NCT01613729</DOCNO>
	<brief_summary>The primary objective study compare efficacy Rosuvastatin 5 mg daily Rosuvastatin 10 mg daily assessment number patient hypercholesterolemia reach LDL-C target goal &lt; 100 mg/dL 12 week therapy .</brief_summary>
	<brief_title>Efficacy Safety Study 5 mg 10 mg Rosuvastatin</brief_title>
	<detailed_description>This study observe following : 1 . To compare effect 5 mg/10 mg Rosuvastatin assessment number patient reach LDL-C target goal 24 week therapy . 2 . To compare effect 12 week therapy 5 mg/10 mg Rosuvastatin change LDL-C ( compare change baseline ) . 3 . To investigate effect 12 week therapy 10 mg Rosuvastatin change LDL-C ( compare value week 0 vs. week 12 ) . 4 . To investigate safety Rosuvastatin regard liver enzyme change , kidney function muscle toxicity . 5 . To compare effect 12 week therapy 5 mg/10 mg Rosuvastatin change TC , HDL-C , TG , LDL-C density HbA1c ( compare change baseline ) . 6 . To investigate effect 12 week therapy 10 mg Rosuvastatin change TC , HDL-C , TG , LDL-C density HbA1c ( compare value week 0 vs. week 12 ) . 7 . To investigate effect 12 week therapy change microalbuminuria treatment group ( compare change baseline ) . 8 . To investigate effect 12 week therapy change BMI ( compare change baseline ) . The effect dose increase dose decrease week 12 24 evaluated follow : 9 . To investigate change LDL-C increase dose 5 mg 10 mg ( compare value week 12 vs. 24 ) . 10 . To investigate change LDL-C decreasing dose 10 mg 5 mg ( compare value week 12 vs. 24 ) . 11 . To investigate change TC , HDL-C , TG , LDL-C density HbA1c increase dose 5 mg 10 mg ( compare value week 12 vs. 24 ) . 12 . To investigate change TC , HDL-C , TG , LDL-C density HbA1c decrease dose 10 mg 5 mg ( compare value week 12 vs. 24 ) .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Age 45 75 year LDL C 130 mg/dL 250 mg/dL TG &lt; 400 mg/dL HbA1c &lt; 7 % Written inform consent participate trial Known hypersensitivity history SAE another HMGCoA reductase inhibitor , particular history myopathy Active liver disease/severe hepatic impairment Treatment cyclosporin disallow drug Patients unstable angina pectoris</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Dyslipidemia</keyword>
	<keyword>Rosuvastatin</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>